News Headlines Article

Gilead’s pricier, next-generation hepatitis C pill wins FDA approval
San Francisco Business Times

Regulators approved Gilead Sciences Inc.’s next-generation hepatitis C drug Friday as the company’s controversial breakthrough treatment continues to rack up sales. Harvoni — combining Sovaldi, the hep C drug that won Food and Drug Administration approval in December, with the drug ledipasvir — will cost $94,500 for a 12-week course of treatments for patients with genotype 1 infection or about $63,000 for an eight-week course, according to reports.